



## Mucosal Responses in the Context of Natural Immunity to HIV

Guest Editor:

**Dr. Johanne Poudrier**

Département de Microbiologie,  
Infectiologie et Immunologie,  
Université de Montréal, Montréal,  
QC, Canada

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

Approximately 37 million people are living with HIV/AIDS worldwide. Most HIV infections are acquired through heterosexual intercourse, and in Africa, nearly 60% of new infections affect women. Currently, there is no cure and the development of vaccines and microbicides remains the best solution to eradicate the pandemic. To this end, the development of effective devices will benefit from studies of individuals who are highly-exposed to HIV and yet remain seronegative (HESN) despite several years of exposure. This special issue aims to further our comprehension of the immune responses that govern mucosal ports of entry in individuals presenting natural immunity to HIV. We therefore encourage the presentation of recent advances in this field. Lessons from vaccination trials and passive immunization studies, and those with non-human primates will also be welcome. Understanding the nature and how immune populations are recruited and maintained within mucosal niche to fight HIV is important to the design of effective preventive/therapeutic approaches.

Dr. Johanne Poudrier

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

Vaccines Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)